Initial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: A Clinical Observation Study on Six Patients
This study is the first report that demonstrates the clinical efficacy of lanadelumab and safety of LTP in HAE patients from Chinese mainland. A reasonable dosage plan can ensure a quick and long-lasting protective role of lanadelumab against HAE attacks, during COVID-19 pandemic period.
Authors
- Bohui Li (ORCID: https://orcid.org/0000-0002-5212-334X)
- Yongmei Yu (ORCID: https://orcid.org/0000-0001-7394-8079)
- Boyun Yang (ORCID: https://orcid.org/0000-0001-6221-2461)
- Rongfei Zhu (ORCID: https://orcid.org/0000-0003-2103-3381)
- Ting Li (ORCID: https://orcid.org/0000-0002-9614-1566)
- Wo Yao (ORCID: https://orcid.org/0000-0002-3794-7308)
- Huiying Wang
- Ran Diao
- Yongfang Wang (ORCID: https://orcid.org/0000-0002-4804-3566)
- Liuya Ge
Institutions
- Kunming Medical University (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- International Archives of Allergy and Immunology
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1159/000541242
- Citations
- 5
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 2.19
Funders
- Zhejiang University